bluebird bio, Inc. (BLUE) Shares Sold by Schroder Investment Management Group
Schroder Investment Management Group reduced its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 50.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,322 shares of the biotechnology company’s stock after selling 6,482 shares during the period. Schroder Investment Management Group’s holdings in bluebird bio were worth $580,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in BLUE. FMR LLC increased its stake in bluebird bio by 9.2% in the fourth quarter. FMR LLC now owns 6,088,971 shares of the biotechnology company’s stock valued at $375,689,000 after buying an additional 513,477 shares during the last quarter. Norges Bank acquired a new stake in bluebird bio during the fourth quarter valued at approximately $22,940,000. Alyeska Investment Group L.P. acquired a new stake in bluebird bio during the fourth quarter valued at approximately $18,270,000. Deerfield Management Co. increased its stake in bluebird bio by 34.8% in the fourth quarter. Deerfield Management Co. now owns 302,027 shares of the biotechnology company’s stock valued at $18,635,000 after buying an additional 78,027 shares during the last quarter. Finally, Arrowpoint Asset Management LLC increased its stake in bluebird bio by 14.2% in the fourth quarter. Arrowpoint Asset Management LLC now owns 453,354 shares of the biotechnology company’s stock valued at $27,972,000 after buying an additional 56,457 shares during the last quarter.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 108.75 on Friday. The stock’s market capitalization is $4.45 billion. The stock’s 50 day moving average price is $91.57 and its 200-day moving average price is $81.07. bluebird bio, Inc. has a 52-week low of $36.62 and a 52-week high of $116.90.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.76) by $0.08. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. The firm had revenue of $6.83 million for the quarter, compared to the consensus estimate of $1.51 million. On average, equities analysts expect that bluebird bio, Inc. will post ($6.74) EPS for the current fiscal year.
BLUE has been the subject of several research analyst reports. BTIG Research reiterated a “buy” rating on shares of bluebird bio in a report on Monday, May 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a report on Friday, March 24th. Zacks Investment Research upgraded bluebird bio from a “sell” rating to a “hold” rating in a report on Monday, May 8th. Cantor Fitzgerald set a $37.00 price objective on bluebird bio and gave the stock a “sell” rating in a report on Monday, June 5th. Finally, Morgan Stanley lifted their price objective on bluebird bio from $87.00 to $91.00 and gave the stock an “equal weight” rating in a report on Monday, May 8th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $94.61.
In other news, insider Philip D. Gregory sold 1,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $99.04, for a total value of $148,560.00. Following the sale, the insider now owns 37,279 shares in the company, valued at $3,692,112.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Lynch sold 3,000 shares of the company’s stock in a transaction dated Monday, March 27th. The stock was sold at an average price of $88.12, for a total value of $264,360.00. Following the completion of the sale, the director now owns 3,400 shares in the company, valued at approximately $299,608. The disclosure for this sale can be found here. Insiders sold 34,258 shares of company stock worth $3,263,236 in the last 90 days. Company insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.